Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study

Stefan Esser, A. Haberl, F. Mulcahy, J. Gölz, A. Lazzarin, E. Teofilo, J. Vera, A. Körber, S. Staszewski

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To assess efficacy, adherence and tolerability of once daily antiretroviral therapy containing tenofovir disoproxil fumarate (DF) 300 mg in HIV-1-infected former injecting drug users receiving opiate treatment (IVDU). Methods: European, 48-week, open-label, single-arm, multicenter study. Patients were either antiretroviral therapy-naïve, restarting therapy after treatment discontinuation without prior virological failure or switching from existing stable treatment. Results: Sixty-seven patients were enrolled in the study and 41 patients completed treatment. In the primary analysis (intent-to-treat missing=failure) at week 48, 34% of patients (23/67; 95% CI: 23%-47%) had plasma HIV-1 RNA

Original languageEnglish
Pages (from-to)427-436
Number of pages10
JournalEuropean Journal of Medical Research
Volume16
Issue number10
Publication statusPublished - Oct 10 2011

Keywords

  • HIV-1
  • Injecting drug users
  • Methadone
  • Tenofovir DF

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study'. Together they form a unique fingerprint.

Cite this